Our portfolio of #GPCR#fluorescent ligands is growing.
We have just added to our catalogue more fluorescent ligands for the AT1 receptor, CELT-145 and CELT-252.
The Angiotensin AT1 receptor belongs to the GPCR superfamily and mediates several physiological actions of the vasoconstricting peptide Angiotensin II, among them regulation of blood pressure, electrolyte and water balance, thirst, hormone secretion, and renal function.
AT1 receptors are present in the human vasculature, lung, liver, brain, kidney, adrenal gland, skin, and endometrium. The AT1 receptor furthermore controls cellular growth, adhesion, migration, and intercellular matrix deposition, influencing chronic adaptive changes in vascular and cardiac growth, remodelling, repair, and atherosclerosis. On the other hand, the expression of AT1 receptors is altered by various pathophysiological conditions: renovascular hypertension, myocardial infarction, ventricular hypertrophy, and bilateral nephrectomy.
At the molecular level, AT1 receptors interact and signal with G proteins and β-arrestin. In addition, AT1 receptor communicates with growing numbers of AT1 receptor–interacting proteins including other GPCRs (heterodimer formation), being involved in a complex signalling network that has been the object of intense study in the last decades.
However, further research is desired regarding the physiological and pathophysiological roles of AT1 receptor and its signalling pathways. For carrying out those studies it is key to count on adequate research tools, like the two new fluorescent ligands exclusively developed by Celtarys Research. CELT-145 and CELT-252 are highly potent and selective fluorescent antagonists for AT1 receptor, with Ki of 160nM and 39 nM, respectively.
They allow to perform qualitative and quantitative fluorescence-based assays such as confocal microscopy, high-content screening and Fluorescence Polarization.
Moreover, their two different excitation/emission wavelengths -at 646/662 and 560/571 respectively- make our probes suitable for different equipment and multiplex settings.


PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS

EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery



Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.

Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women





Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)



Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.




Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment





NEOTEC · CDTI — Ministerio de Ciencia e Innovación




The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024
Avenida de Barcelona, 7
15706, Santiago de Compostela
A Coruña (Spain)